Workflow
Nasdaq(NDAQ)
icon
Search documents
Nasdaq Trading Near 52-Week High: How Should You Play the Stock?
ZACKS· 2024-10-02 16:35
Shares of Nasdaq Inc. (NDAQ) closed at $73.05 on Tuesday, near its 52-week high of $74.88, after having gained 21.4% in the past three months. Shares outperformed the industry, the Finance sector as well as the Zacks S&P 500 composite index in the same time frame.Earnings of this company increased 12.7% in the last five years, better than the industry average of 9.8%. Nasdaq has been successful in maximizing opportunities as a technology and analytics provider and growing core marketplace business. Its focu ...
Banzai Granted Extension by Nasdaq Hearing Panel to Regain Compliance with Continued Listing Requirements
GlobeNewswire News Room· 2024-10-02 12:31
SEATTLE, Oct. 02, 2024 (GLOBE NEWSWIRE) -- Banzai International, Inc. (NASDAQ: BNZI) (“Banzai” or the “Company”), a leading marketing technology company that provides essential marketing and sales solutions, today announced that it received notice from the Nasdaq Listing Qualifications Panel (the “Hearings Panel”) of The Nasdaq Stock Market LLC (“Nasdaq”) that the Hearings Panel has granted the Company’s request to continue its listing on The Nasdaq Stock Market, subject to the Company meeting certain condi ...
Nasdaq Ends 1.5% Lower As Tesla, Nvidia, And Apple Fall: Investor Optimism Declines, Fear Index Remains In 'Greed' Zone
Benzinga· 2024-10-02 07:01
The CNN Money Fear and Greed index showed a decline in the overall market sentiment, while the index remained in the “Greed” zone on Tuesday.U.S. stocks settled lower on Tuesday, with the Dow Jones index falling more than 150 points amid growing concerns in the Middle East.Most of the major tech stocks closed lower on Tuesday. Shares of Tesla Inc. TSLA, Nvidia Corp. NVDA, and Apple Inc. AAPL all closed the day lower.On the economic data front, construction spending in the U.S. declined by 0.1% month-over-mo ...
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire News Room· 2024-10-01 20:05
BOSTON, Oct. 01, 2024 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today announced that, effective on September 30, 2024, the company issued inducement awards to new employees under the X4 Pharmaceuticals, Inc. 2019 Inducement Equity Incentive Plan (the “2019 Inducement Plan”). The 2019 Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously an employee of X4. ...
Sagimet Biosciences to Present at the H.C. Wainwright 8th Annual MASH Virtual Conference and Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire News Room· 2024-10-01 04:05
SAN MATEO, Calif., Oct. 01, 2024 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Sagimet, Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel fatty acid synthase (FASN) inhibitors designed to target dysfunctional metabolic and fibrotic pathways, today announced that management will participate in a virtual fireside chat at the H.C. Wainwright 8th Annual MASH Virtual Conference at 2:30 PM ET on Monday, October 7, 2024. A live webcast of the fireside chat will be available in the Investor ...
111, Inc. Announces Receipt of Notification from Nasdaq
Prnewswire· 2024-09-27 21:00
SHANGHAI, Sept. 27, 2024 /PRNewswire/ -- 111, Inc. ("111" or the "Company") (NASDAQ: YI), a leading tech-enabled healthcare platform company committed to reshaping the value chain of healthcare industry by digitally empowering the upstream and downstream in China, today announced it has received a notification letter dated September 26, 2024 (the "Notice") from the staff of the Listing Qualifications Department of The Nasdaq Stock Market LLC ("Nasdaq"), indicating that for the last 30 consecutive business d ...
PetMed Express, Inc. Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire News Room· 2024-09-27 20:17
DELRAY BEACH, Fla., Sept. 27, 2024 (GLOBE NEWSWIRE) -- PetMed Express, Inc., dba PetMeds and parent company of PetCareRx, (Nasdaq: PETS), today announced that on September 27, 2024, PetMeds granted two equity awards previously approved by its Board of Directors to two newly hired executives as a material inducement to employment. PetMeds granted Doug Krulik, Chief Accounting Officer, 40,000 time-based restricted stock units (“RSUs”) and granted Robyn D’Elia, Chief Financial Officer, 250,000 time-based RSUs. ...
Beyond Air Announces $20.6 Million Private Placement Offering Priced At-the-Market Under Nasdaq Rules
GlobeNewswire News Room· 2024-09-27 11:30
– Financing strengthens balance sheet and is expected to provide sufficient cash runway through June 2026 –       – Retiring $17.5 million in Avenue Capital debt, aided by $11.5 million in new debt from insider-led group; eliminates $12 million in scheduled debt payments through June 2026 – – Avenue Capital, current insiders, and select group of healthcare-focused investment funds participated in the equity offering – GARDEN CITY, N.Y., Sept. 27, 2024 (GLOBE NEWSWIRE) --  Beyond Air, Inc. (NASDAQ: XAIR) (“B ...
Banzai Announces Closing of $5 Million Private Placement Priced At-The-Market Under Nasdaq Rules
GlobeNewswire News Room· 2024-09-26 23:30
SEATTLE, Sept. 26, 2024 (GLOBE NEWSWIRE) -- Banzai International, Inc. (NASDAQ: BNZI) (“Banzai” or the “Company”), a leading marketing technology company that provides essential marketing and sales solutions, today announced the closing of its previously announced private placement priced at-the-market under the rules of the Nasdaq Stock Market for the issuance and sale of an aggregate of 1,176,471 shares of Class A common stock (or pre-funded warrant in lieu thereof), accompanying Series A warrants to purc ...
Pasithea Therapeutics Announces $5 Million Private Placement Priced At-The-Market Under Nasdaq Rules
GlobeNewswire News Room· 2024-09-26 22:44
MIAMI, Sept. 26, 2024 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ: KTTA) (“Pasithea” or the “Company”), a clinical-stage biotechnology company developing PAS-004, a next-generation macrocyclic MEK inhibitor, for the treatment of neurofibromatosis type 1 (NF1) and other cancer indications, today announced that it has entered into definitive agreements for the issuance and sale of an aggregate of 1,219,513 shares of its common stock (or pre-funded warrants in lieu thereof), accompanying Series A w ...